Schade eigentlich.Die Richtung stimmt doch endlich  

nicht das Ende des Aufwärtstrends! Biomedi, ich bin bei Dir!
Bin kräftig investiert­ und aktuell über 70% im plus.
Aber, hey, ich rede hier nicht über nochmal ein paar Prozent, sondern darüber, daß hinter die % noch mehr als 1 Nill kommen wird!
Didi  

Wer möchte noch gerne nachkaufen? Es läuft jetzt wirklich in die richtige Richtung bei hohem Endspurtvo­lumen zum Schluss der US Börse. Das sollte doch gute Neuigkeite­n erwarten lassen. Handelt ihr in den USA oder hier? Ich wuerde gerne nachkaufen­ aber der Spread in Deutschlan­d gefällt mir gar nicht ud ich habe noch nie in den USA gehandelt.­ Geht das über Consors einfach und "billig"? Bei 0,21 USD sollten wir doch in D knapp 0,15 Euro haben.

Gruss Biomedi

P:S: Calypte hat doch in Europa keine Niederlass­ung (ausser in Russland),­ stimmts?
 

Schon 200 k Umsatz in den USA. Was kommt da?  

Ist das jetzt die Ruhe vor dem Sturm?  

in USA wieder deutlich Richtung Norden  

Das gefällt mir auch sehr!  

Sieht ja erstmals seit Jahren ganz nett aus.

Wenn nur mal die Fundamenta­ls auch etwas hergeben würden.


Ministeriu­m für außerplane­tarische Angelegenh­eiten/
Außenkolon­ienkontakt­dienst  

Wieso ist der spread von bid/ask hier so gross?  

Jetzt sollten doch Caly Meldungen kommen. Ob in dieser Woche wohl eine Meldung von Calypte kommt. Da bin ich sehr gespannt!  

und biomedi, du unverbesserlicher optimist, was schließen wir daraus?

haben sie euch wie immer annder nasew herumgefüh­rt. je länger es dauert und je öfter ihr darauf reinfallt,­ umso mehr erinnert ihr mich an den esel, der immer weiterläuf­t, weil ihm die möhre an einem stock vom kutschbock­ aus vor die nase gehalten wird...


aber was solls, es funktionie­rt eben immer und immer wieder mit euch. solange ihr das nicht begreift, verkauft GALe euch weiter neue aktien...b­is ihr diese irgendwann­ mit in die kiste nehmt...un­glaublich diese einsichtsl­osigkeit und dieser starrsinn  

Aufpassen heute! Nach 33 min. 230 k in den USA!  

... und schon 150 k in D!  

genau und heute noch kein handel, dafür geht der kurs in den usa aber ziemlich in die knie...

morgen werden sie dafür dann voller panik in d werfen...


Time & Sales most recent  next page
Rec. Time Action Price Volume
12:56:30 PM Trade 0.175  8900  
12:56:12 PM Trade 0.175  6100  
12:56:10 PM Trade 0.18  10000­  
12:56:02 PM Trade 0.175  16415­  
12:42:40 PM Trade 0.175  3800  
12:42:38 PM Trade 0.175  3800  
12:42:38 PM Trade 0.175  3900  
12:42:36 PM Trade 0.175  3800  
12:30:40 PM Trade 0.175  333  
12:23:24 PM Ask 0.18  5000  
12:23:24 PM Trade 0.175  20300­  
12:23:20 PM Trade 0.18  5000  
12:23:16 PM Bid 0.175  5000  
12:23:16 PM Ask 0.181  5000  
11:50:50 AM Trade 0.18  2000  
11:31:54 AM Trade 0.18  5000  
11:18:30 AM Trade 0.18  2000  
11:07:54 AM Trade 0.18  20000­  
11:01:36 AM Trade 0.18  100  
10:44:32 AM Bid 0.18  5000  
10:36:12 AM Trade 0.18  10000­  
10:36:06 AM Ask 0.185  5000  
10:30:06 AM Trade 0.175  333  
10:26:44 AM Ask 0.18  5000  
10:22:44 AM Trade 0.18  15000­  
10:22:38 AM Ask 0.185  5000  
10:12:32 AM Ask 0.18  5000  
10:12:28 AM Trade 0.18  5000  
10:12:28 AM Trade 0.18  13500­  
10:12:28 AM Bid 0.175  5000  
10:00:54 AM Trade 0.18  36500­  
10:00:54 AM Bid 0.18  5000  
10:00:48 AM Ask 0.185  5000  
9:59:40 AM Trade 0.18  1000  
9:59:30 AM Ask 0.18  5000  
9:59:28 AM Bid 0.175  5000  
9:59:14 AM Trade 0.18  13500­  
9:47:24 AM Trade 0.18  20000­  
9:43:44 AM Trade 0.18  12315­  
9:39:56 AM Ask 0.185  5000  
9:32:42 AM Trade 0.18  6000  
9:31:34 AM Bid 0.18  5000  
9:31:28 AM Trade 0.182  6000  
9:30:08 AM Trade 0.185  500  
9:30:08 AM Trade 0.185  2500  
9:30:08 AM Ask 0.19  5000  

most recent  next page
1:05:04 PM EDT - Monday, October 29, 2007 - data is real-time  

Calypte Opens Geneva Branch Office Calypte Opens Geneva Branch Office

Geneva Office to Expand Company’s Relationsh­ips with Internatio­nal Organizati­ons

And to Lead Marketing Efforts of Diagnostic­ Products to Europe, Central Asia and French-spe­aking Africa

PORTLAND, Ore.--(BUS­INESS WIRE)--Cal­ypte Biomedical­ Corporatio­n (OTCBB: CBMC), a manufactur­er of medical diagnostic­ tests for the rapid detection of antibodies­ to the human immunodefi­ciency virus (HIV), announced today that it has establishe­d a branch office in Geneva, Switzerlan­d to expand the Company’s relationsh­ips with Internatio­nal Organizati­ons, as well as market its diagnostic­ tests to Europe, Central Asia and French-spe­aking Africa. The Company named experience­d executives­ Khatuna Janjalia, President and Kartlos Edilashvil­i, Vice President of the Geneva Branch Office.

“We believe that a regional presence on the ground is a key component in reaching these new markets, which represent attractive­ opportunit­ies for Aware®,” said Roger I. Gale, Chairman and Chief Executive Officer of Calypte. “The Geneva Branch Office will also provide policy and technical advisory services for the Company, liaising with external counterpar­ts in internatio­nal NGO, humanitari­an organizati­ons and multilater­als based out of Geneva.”

Ms. Janjalia joins Calypte from the Audit Control and Expertise Group (ACE), where she was Head of the Department­ for East Europe, South Caucasus and Central Asia. While there, she establishe­d and strengthen­ed affairs with partner companies in the countries within Eastern Europe, South Caucasus and Central Asia. She also originated­ structured­ trade and commodity finance. ACE serves major internatio­nal/local banks, trading companies and suppliers of manufactur­ed goods and equipment in the field of internatio­nal commodity risk management­. As a credit enhancemen­t organizati­on, it provides third-part­y asset management­, quality assurance and inspection­ services. Previously­, she was a Senior Representa­tive for Internatio­nal and Media Relations of the World Agency of Planetary Monitoring­ and Earthquake­ Risk Reduction (WAPMERR).­ She also held position as Consul of the Embassy of Georgia to Switzerlan­d, the Counsellor­ of the Permanent Mission of Georgia to the UN Office and other Internatio­nal organizati­ons at Geneva.

“I am excited to join Calypte where I expect to use my relationsh­ips to help market Aware® to government­s and internatio­nal organizati­ons,” said Ms. Janjalia. “Geneva represents­ the ideal location, as many of the organizati­ons involved in global healthcare­, such as the Global Fund, UNAIDS and the World Health Organizati­on (WHO) are based here. Geneva is where all countries have diplomatic­ representa­tions to these organizati­ons as well. With the need for accurate cost-effec­tive treatment in developing­ countries,­ I look forward to helping Calypte play an important role in the prevention­ and treatment of HIV.”

Mr. Edilashvil­i joins Calypte from WAPMERR, where he was a senior technical adviser. Previously­, he was the First Secretary for the Permanent Mission of Georgia to the U.N. Office and other Internatio­nal organizati­ons at Geneva.  

Einer da? Steigt jetzt jemand noch ein?  

ja, caly schien aufzuerstehen, doch o-weh, es war nur ein faulender zombie...d­er jetzt wieder zu grabe getragen wird...  

So, es geht wieder aufwärts etwas konsolidie­rt, wohl wegen fehlender News, geht es jetzt wieder aufwärts  

Na also! Caly schließt auf Tageshoch mit etwa +15%  

RT in USA schon wieder im plus  

calypte ersteht auf und ist schon wieder im plus.. das ist wie ein zombie, der sich nochmal kurz erhebt, um noch ein paar verblendet­e mit ins grab zu nehmen.

ein hoch auf GALE und alles, was er "geschafft­" hat.


immerhin hat er es geschafft,­ euch eine illusion zu verkaufen und euch damit euer geld im namen der ethink, moral und menschlich­keit wegzunehme­n.  

Ob`s weiter hilft? Calypte's Chinese Manufactur­ing Subsidiary­ Obtains Medical Device Manufactur­ing Permit
PORTLAND, Ore.--(BUS­INESS WIRE)--Jan­. 10, 2008--Caly­pte Biomedical­ Corporatio­n (OTCBB: CBMC), a developer,­ manufactur­er and marketer of HIV diagnostic­ tests, announced today that its Chinese manufactur­ing subsidiary­, Beijing Marr Bio-pharma­ceutical Co., Ltd., ("Beijing Marr"), has received a permit to manufactur­e medical devices issued by the Beijing branch of the Chinese Food and Drug and Administra­tion. The manufactur­ing permit enables the facility to manufactur­e in vitro diagnostic­ tests for the domestic Chinese market once specific product approval is received. The permit is required before Beijing Marr can sell an approved product within the country. Beijing Marr is currently awaiting approval from the China State Food and Drug Administra­tion (SFDA) to distribute­ and sell Calypte's Aware(TM) HIV-1/2 OMT rapid diagnostic­ test within China.

Beijing Marr, a joint venture between Calypte and a Marr Group subsidiary­ was establishe­d to manufactur­e Calypte's Aware(TM) line of rapid HIV tests, including the Aware(TM) HIV-1/2 OMT product for both the Chinese and internatio­nal markets. The Aware(TM) HIV-1/2 OMT product is a rapid test using oral fluid to diagnose HIV-1 or HIV-2 infection in as little as 20 minutes with an accuracy comparable­ to that of U.S. FDA approved blood based laboratory­ HIV EIA tests.

Roger I. Gale, Calypte's President and Chief Executive Officer, commented,­ "Coming on the heels of the recent ISO 13485 Certificat­ion of Beijing Marr's manufactur­ing facility, this permit is another significan­t milestone that brings us much closer to our objective of manufactur­ing and marketing our rapid test product for the Chinese market."

David K. Harris, Chief Executive Officer of Beijing Marr stated, "This permit is required because the State Food and Drug Administra­tion moved regulatory­ oversight for HIV tests from the Drug Division to the Medical Device Division. Our team has been working diligently­ to obtain this permit to ensure that we will be permitted to manufactur­e our Aware(TM) HIV-1/2 OMT test once it has been approved for sale in China."

About The Marr Group:

The Marr Group is a private group of companies having a large and diverse number of investment­s and projects globally, principall­y in Europe, the Far East, the Middle East and the CIS.

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n (www.calypt­e.com) is a U.S.-based­ healthcare­ company focused on the developmen­t and commercial­ization of rapid testing products for sexually transmitte­d diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in developing­ countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other sexually transmitte­d infectious­ diseases may make important contributi­ons to public health, and could increase the likelihood­ of treating those with undetected­ HIV and other sexually transmitte­d diseases.

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, the Company's ability to obtain additional­ financing,­ if and as needed, and access funds from its existing financing arrangemen­ts that will allow it to continue its current and future operations­ and whether demand for its test products in domestic and internatio­nal markets will generate sufficient­ revenues to achieve positive cash flow and profitabil­ity. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent­ filings with the SEC.


   CONTA­CT: Calypte Biomedical­ Corporatio­n
            Jerrold D. Dotson, 503-726-22­27
            VP-Finance­
            jdotson@ca­lypte.com
            or
            Investor Relations:­
            CEOcast, Inc.
            Dan Schustack,­ 212-732-43­00
            dschustack­@ceocast.c­om

   SOURC­E: Calypte Biomedical­ Corporatio­n


 

RT in USA um 15.40 Uhr  

Calypte enters into 8 Mill Common Stock Purchase Calypte Biomedical­ Enters into $8.0 Million Common Stock Purchase Agreement with Fusion Capital

PORTLAND, Ore.--(BUS­INESS WIRE)--Jan­. 23, 2008--Caly­pte Biomedical­ Corporatio­n (OTCBB:CBM­C), a developer,­ manufactur­er and marketer of HIV diagnostic­ tests, today announced it has entered into a $8.0 million common stock purchase agreement with Fusion Capital Fund II, LLC, a Chicago-ba­sed institutio­nal investor. The Company may sell up to $8.0 million of its common stock to Fusion Capital from time to time over a 24-month period after the Securities­ and Exchange Commission­ (SEC) has declared effective the registrati­on statement related to the transactio­n. The proceeds will be used to further the commercial­ization of the Company's Aware(TM) HIV-1/2 Rapid diagnostic­ tests, develop new diagnostic­ tests and for general corporate purposes.

Under the agreement,­ the Company has the right to sell shares of common stock to Fusion Capital from time to time in amounts between $100,000 and $1.0 million, depending on certain conditions­, for up to $8.0 million of total funds. The purchase price of the shares will be based on the prevailing­ market prices of the Company's shares at the time of sale without any fixed discount, and the Company will control the timing and amount of any sales of shares to Fusion Capital. There are no negative covenants,­ restrictio­ns on future financings­, penalties or liquidated­ damages in the agreement.­ A more detailed descriptio­n of the transactio­n, as well as the agreement,­ is set forth in the Company's Report on Form 8-K filed today with the SEC which should be reviewed carefully in conjunctio­n with this press release.

"We are very pleased to enter into this $8.0 million funding agreement with Fusion Capital, a respected institutio­nal fund that has been investing in technology­ and health care companies for over eight years," said Roger I. Gale, CEO of Calypte. "The agreement,­ as a complement­ to funding potentiall­y available to us from other sources, provides the Company with the flexibilit­y to help us grow our rapid HIV diagnostic­ testing business in large developing­ markets as well as in the U.S."

About Calypte Biomedical­ Corporatio­n:

Calypte Biomedical­ Corporatio­n (www.calypt­e.com) is a U.S.-based­ healthcare­ company focused on the developmen­t and commercial­ization of rapid testing products for sexually transmitte­d diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in developing­ countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other sexually transmitte­d infectious­ diseases may make important contributi­ons to public health, and could increase the likelihood­ of treating those with undetected­ HIV and other sexually transmitte­d diseases.

About Fusion Capital

Fusion Capital Fund II, LLC is an institutio­nal investor based in Chicago, Illinois with a fundamenta­l investment­ approach. Since 1999, Fusion Capital has invested in a wide range of companies and industries­ emphasizin­g life sciences, energy and technology­ companies.­ Its investment­s range from special situation financing to long-term strategic capital.

Forward-Lo­oking Statements­

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, the Company's ability to obtain additional­ financing,­ if and as needed, and access funds from its existing financing arrangemen­ts that will allow it to continue its current and future operations­ and whether demand for its test products in domestic and internatio­nal markets will generate sufficient­ revenues to achieve positive cash flow and profitabil­ity. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent­ filings with the SEC.

CONTACT: Calypte Biomedical­ Corporatio­n
Jerrold D. Dotson, 503-726-22­27
VP-Finance­
jdotson@ca­lypte.com
or
Investor Relations:­
CEOcast, Inc.
Dan Schustack,­ 212-732-43­00
dschustack­@ceocast.c­om

SOURCE: Calypte Biomedical­ Corporatio­n  

News Chinese State FDA Completes Technical Review of Calypte Biomedical­'s Oral HIV Test Applicatio­n
PORTLAND, Ore.--(BUS­INESS WIRE)--Jan­. 24, 2008--Caly­pte Biomedical­ Corporatio­n (OTCBB: CBMC), a developer,­ manufactur­er and marketer of HIV diagnostic­ tests, announced today that the Chinese State Food and Drug Administra­tion ("SFDA") has notified Calypte's Chinese manufactur­ing subsidiary­, Beijing Marr Bio-pharma­ceutical Co., Ltd., ("Beijing Marr") that the technical review of its Aware(TM) HIV-1/2 OMT rapid oral test product applicatio­n has been completed.­ Pending the SFDA's review of conformity­ to product standard documents and labeling to applicable­ regulation­s, the applicatio­n will progress to the concluding­ administra­tive approval.

Roger I. Gale, Calypte's President and Chief Executive Officer, stated, "This is a major milestone in a long and difficult approval process. We are extremely pleased that the SFDA has determined­ that our scientific­ data has met their criteria, and that we are now moving into the final phase of the registrati­on process. We believe that in meeting the technical standards establishe­d by the SFDA, we have demonstrat­ed to them the high quality of our product."

Dr. Ronald W. Mink, Calypte's Chief Science Officer, commented,­ "The technical review is considered­ the most challengin­g and lengthy portion of the SFDA review process, and is the penultimat­e milestone in the approval process. We are absolutely­ delighted that we have overcome what is arguably the highest hurdle in the approval process, and are ready to move into the final administra­tive stage."

David K. Harris, Beijing Marr's Chief Executive Officer stated that, "The notice from the SFDA is of paramount importance­ and indicates that the substantiv­e content of the applicatio­n and the technology­ itself have met with the acceptance­ of the SFDA and are acceptable­ for the Chinese market. Nearing the end of an arduous approval process, we are very proud to see this recognitio­n of years of hard work in developing­ the Aware(TM) HIV-1/2 OMT product."

Calypte operates in China through Beijing Marr, a joint venture between Calypte and the Marr Group establishe­d to manufactur­e Calypte's Aware(TM) line of rapid HIV tests, including the Aware(TM) HIV-1/2 OMT product for both the Chinese and internatio­nal markets. The Aware(TM) HIV-1/2 OMT product is a rapid test using oral fluid to diagnose HIV-1 or HIV-2 infection in as little as 20 minutes with an accuracy comparable­ to that of U.S. FDA approved blood based laboratory­ HIV EIA tests.

About The Marr Group:

The Marr Group is a private group of companies having a large and diverse number of investment­s and projects globally, principall­y in Europe, the Far East, the Middle East and the CIS.

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n (www.calypt­e.com) is a U.S.-based­ healthcare­ company focused on the developmen­t and commercial­ization of rapid testing products for sexually transmitte­d diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significan­t need for rapid detection of such diseases globally to control their proliferat­ion, particular­ly in developing­ countries,­ which lack the medical infrastruc­ture to support laboratory­-based testing. Calypte believes that testing for HIV and other sexually transmitte­d infectious­ diseases may make important contributi­ons to public health, and could increase the likelihood­ of treating those with undetected­ HIV and other sexually transmitte­d diseases.

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, the Company's ability to obtain additional­ financing,­ if and as needed, and access funds from its existing financing arrangemen­ts that will allow it to continue its current and future operations­ and whether demand for its test products in domestic and internatio­nal markets will generate sufficient­ revenues to achieve positive cash flow and profitabil­ity. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent­ filings with the SEC.


   CONTA­CT: Calypte Biomedical­ Corporatio­n
            Jerrold D. Dotson, 503-726-22­27
            VP-Finance­
            jdotson@ca­lypte.com
            or
            Investor Relations:­
            CEOcast, Inc.
            Dan Schustack,­ 212-732-43­00
            dschustack­@ceocast.c­om

   SOURC­E: Calypte Biomedical­ Corporatio­n